Regencell Bioscience Holdings (Regencell Bioscience Holdings) Net Cash per Share

: $0.84 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Regencell Bioscience Holdings's Net Cash per Share for the quarter that ended in Jun. 2023 was $0.84.

The historical rank and industry rank for Regencell Bioscience Holdings's Net Cash per Share or its related term are showing as below:

RGC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.61 Med: 28.26 Max: 29.08
Current: 7.67

During the past 5 years, the highest Price-to-Net-Cash Ratio of Regencell Bioscience Holdings was 29.08. The lowest was 6.61. And the median was 28.26.

RGC's Price-to-Net-Cash is ranked better than
50.38% of 266 companies
in the Drug Manufacturers industry
Industry Median: 7.71 vs RGC: 7.67

Regencell Bioscience Holdings Net Cash per Share Historical Data

The historical data trend for Regencell Bioscience Holdings's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Net Cash per Share

-0.15

-0.22

-0.34

1.19

0.84

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Cash per Share					-0.34	-0.11	1.19	-0.07	0.84

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Price-to-Net-Cash Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Price-to-Net-Cash falls into.

Regencell Bioscience Holdings Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Regencell Bioscience Holdings's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

	Net Cash per Share (A: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.565	-	0.632	-	-0.041)	/	13.0129
=	0.84

Regencell Bioscience Holdings's Net Cash per Share for the quarter that ended in Jun. 2023 is calculated as

	Net Cash per Share (Q: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.565	-	0.632	-	-0.041)	/	13.0129
=	0.84

Regencell Bioscience Holdings (NAS:RGC) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Regencell Bioscience Holdings Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.